January 24, 2014
1 min read
Save

Single-fraction radiation effective, tolerable for bone metastases palliation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Radiation in a single fraction of 8 Gy appeared noninferior and less toxic than 20 Gy in multiple fractions to palliate pain in patients with bone metastases, according to results of a multicenter study.

The analysis included 850 patients. Researchers randomly assigned 425 patients to each arm between 2004 and 2012.

All patients had radiologically confirmed, painful bone metastases — defined as ≥2 points on the Brief Pain Inventory scale — and had received prior radiation therapy.

Overall pain response — assessed using Brief Pain Inventory scores and changes in analgesic consumption — at 2 months served as the primary endpoint.

At 2 months, 358 patients assigned 8 Gy radiation in a single fraction and 349 patients assigned 20 Gy in multiple fractions were assessable.

In the overall intention-to-treat population, more patients assigned 20 Gy compared with 8 Gy demonstrated and overall pain response to treatment, although the difference was not statistically significant (32% vs. 28%; P=.21).

In the per-protocol population, 51% of patients assigned 20 Gy had an overall pain response to treatment vs. 45% in the 8-Gy cohort (P=.17).

More patients assigned 20 Gy experienced lack of appetite (66% vs. 56%; P=.011) and diarrhea (31% vs. 23%; P=.018) at 14 days.

More patients in the 8-Gy arm experienced pathological fractures (OR=1.54; 95% CI, 0.85-2.75), and spinal cord or cauda equina compressions (OR=3.54; 95% CI, 0.73-17.15).

“In patients with painful bone metastases requiring repeat radiation therapy, treatment with 8 Gy in a single fraction seems to be noninferior and less toxic than 20 Gy in multiple fractions; however, as findings were not robust in a per-protocol analysis, trade-offs between efficacy and toxicity might exist,” the researchers wrote.

Disclosure: The researchers report no relevant financial disclosures.